ResMed Inc.
Michael J. Farrell (Chairman and CEO) sells RMD shares
AI-generated summary
Chairman and CEO, Director Michael J. Farrell exercised options for 4,993 shares for a total of $730,675.62, and sold 4,993 shares for a total of $1,175,089.07 at an average price of $235.35. Following these transactions, the insider directly held 479,803 shares of ResMed Common Stock. The trades were made under a Rule 10b5-1 trading plan adopted on October 31, 2024.
Key facts
- Insider
- Michael J. Farrell · Chairman and CEO, Director
Rule 10b5-1 plan · adopted Oct 31, 2024
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Nov 9, 2026 | M · exercise or conversion of a derivativeFootnotes F1 | +683 | $146.34 | $99,950.22 | 480,486 | Direct |
| Nov 9, 2026 | M · exercise or conversion of a derivativeFootnotes F1 | +4,310 | $146.34 | $630,725.40 | 484,796 | Direct |
| Nov 9, 2026 | S · open-market saleFootnotes F1, F2 | −4,993 | $235.35 | $1,175,089.07 | 479,803 | Direct |
| Nov 9, 2026 | M · exercise or conversion of a derivativeResMed Common Stock OptionsFootnotes F1, F3 | −683 | $0.00 | $0.00 | 4,310 | Direct |
| Nov 9, 2026 | M · exercise or conversion of a derivativeResMed Common Stock OptionsFootnotes F1, F4 | −4,310 | $0.00 | $0.00 | 0 | Direct |
Footnotes
- F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
- F2 This transaction was executed in multiple trades at prices ranging from $231.7956 - $237.600. The price reported above reflects the weighted average sale price.
- F3 Represents date options first become exercisable. Options vest 1/3 per year
- F4 Represents date options first become exercisable. Options vest 1/3 per year
More RMD filings
- 144
Filed Nov 9, 2026
- 8-K
Filed Oct 29, 2026
- 10-Q
Filed Oct 29, 2026
- 4
Filed Oct 26, 2026
- 144
Filed Oct 23, 2026
- 4
Filed Oct 8, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.